Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | BUB1 | O43683 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8564703 | 0.74 | PGR (0.34) | RAB9AMEN1KMT2ABUB1NPSR1 | |
| SCHEMBL9089041 | 0.72 | NPSR1 (0.46) | RAB9AMEN1KMT2ALMNANPSR1 | |
| SCHEMBL21013530 | 0.72 | POLB (0.46) | RAB9AMEN1KMT2AHTTMAPK1 | |
| SCHEMBL29606664 | 0.72 | POLB (0.46) | RAB9AMEN1KMT2AHTTMAPK1 | |
| SCHEMBL6102590 | 0.71 | ALDH1A1 (0.38) | RAB9AMEN1KMT2ALMNANPSR1 | |
| SCHEMBL21084746 | 0.71 | RAB9A (0.35) | RAB9AMEN1KMT2A | |
| SCHEMBL14273273 | 0.70 | TDP2 (0.39) | MEN1KMT2AMAP4K1LMNANPSR1 | |
| Hydrochloric Acid SCHEMBL30504137 | 0.70 | POLB (0.45) | RAB9AMEN1KMT2AHTTMAPK1 | |
| SCHEMBL6105143 | 0.70 | MAPT (0.50) | MEN1KMT2AHTTLMNANPSR1 | |
| SCHEMBL16064982 | 0.70 | OPRM1 (0.46) | MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | RAB9A 2518/4885TGFBR1 1997/4885MEN1 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.